These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Bromocriptine combined with levodopa in Parkinson's disease. Gauthier G; Martins da Silva A Eur Neurol; 1982; 21(4):217-26. PubMed ID: 7117308 [TBL] [Abstract][Full Text] [Related]
8. The impact of treatment with levodopa on Parkinson's disease. Shaw KM; Lees AJ; Stern GM Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763 [TBL] [Abstract][Full Text] [Related]
9. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. Papathanou M; van der Laan R; Jenner P; Rose S; McCreary AC Mov Disord; 2013 Jul; 28(8):1072-9. PubMed ID: 23125107 [TBL] [Abstract][Full Text] [Related]
10. L-tryptophan supplementation in Parkinson's disease. Sandyk R; Fisher H Int J Neurosci; 1989 Apr; 45(3-4):215-9. PubMed ID: 2744962 [TBL] [Abstract][Full Text] [Related]
11. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167 [TBL] [Abstract][Full Text] [Related]
12. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Sweet RD; McDowell FH Ann Intern Med; 1975 Oct; 83(4):456-63. PubMed ID: 1166978 [TBL] [Abstract][Full Text] [Related]
13. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. Kempster PA; Gibb WR; Stern GM; Lees AJ J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):72-6. PubMed ID: 2709038 [TBL] [Abstract][Full Text] [Related]
14. The evolution and origin of motor complications in Parkinson's disease. Obeso JA; Rodriguez-Oroz MC; Chana P; Lera G; Rodriguez M; Olanow CW Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505 [TBL] [Abstract][Full Text] [Related]
15. Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease. Barbeau A; Roy M Neurology; 1976 May; 26(5):399-404. PubMed ID: 944392 [TBL] [Abstract][Full Text] [Related]
16. L-dopa long-term treatment in Parkinson's disease: age-related side effects. Pederzoli M; Girotti F; Scigliano G; Aiello G; Carella F; Caraceni T Neurology; 1983 Nov; 33(11):1518-22. PubMed ID: 6415513 [TBL] [Abstract][Full Text] [Related]
17. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? Vidailhet M; Bonnet AM; Marconi R; Gouider-Khouja N; Agid Y Neurology; 1994 Sep; 44(9):1613-6. PubMed ID: 7936284 [TBL] [Abstract][Full Text] [Related]
18. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Clarke CE; Deane KH Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504 [TBL] [Abstract][Full Text] [Related]
19. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Cedarbaum JM; Gandy SE; McDowell FH Neurology; 1991 May; 41(5):622-9. PubMed ID: 2027475 [TBL] [Abstract][Full Text] [Related]
20. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Tolosa ES; Martin WE; Cohen HP; Jacobson RL Neurology; 1975 Feb; 25(2):177-83. PubMed ID: 1167646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]